公开(公告)号：US08895585B2

公开(公告)日：2014-11-25

申请号：US13730000

申请日：2012-12-28

申请人： Hideyasu Fujiwara ,  Kimihiko Sato ,  Shinsuke Mizumoto ,  Yuichiro Sato ,  Hideki Kurihara ,  Yohei Kubo ,  Hiyoku Nakata ,  Yasutaka Baba ,  Takashi Tamura ,  Hidenobu Kuniyoshi ,  Shinji Hagiwara ,  Mari Yamamoto

发明人： Hideyasu Fujiwara ,  Kimihiko Sato ,  Shinsuke Mizumoto ,  Yuichiro Sato ,  Hideki Kurihara ,  Yohei Kubo ,  Hiyoku Nakata ,  Yasutaka Baba ,  Takashi Tamura ,  Hidenobu Kuniyoshi ,  Shinji Hagiwara ,  Mari Yamamoto

IPC分类号： C07D213/82

CPC分类号： C07D401/12 ,  C07D213/82 ,  C07D215/40 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D491/056 ,  C07D491/107 ,  C07D498/04 ,  C07D513/04

摘要： An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

摘要翻译： 本发明的目的是提供具有优异的Syk抑制活性的化合物和药物组合物。 本发明提供下述式（I）表示的烟酰胺衍生物（其中，R1表示卤素原子，R2表示C1-12烷基，C2-12烯基，C2-12炔基，C3-8 环烷基，芳基，芳基-C 1-6烷基或杂环基，各自任选具有至少一个取代基; R 3表示各自任选具有至少一个取代基的芳基或杂环基;以及R 4和R 5各自 独立地表示氢原子; R2和R4可以形成任选具有至少一个取代基的环状氨基以及与它们结合的氮原子）或其盐，以及用于治疗Syk- 其包含烟酰胺衍生物或其盐。

公开(公告)号：US20130116430A1

公开(公告)日：2013-05-09

申请号：US13730000

申请日：2012-12-28

申请人： Hideyasu FUJIWARA ,  Kimihiko SATO ,  Shinsuke MIZUMOTO ,  Yuichiro SATO ,  Hideki KURIHARA ,  Yohei KUBO ,  Hiyoku NAKATA ,  Yasutaka BABA ,  Takashi TAMURA ,  Hidenobu KUNIYOSHI ,  Shinji HAGIWARA ,  Mari YAMAMOTO

发明人： Hideyasu FUJIWARA ,  Kimihiko SATO ,  Shinsuke MIZUMOTO ,  Yuichiro SATO ,  Hideki KURIHARA ,  Yohei KUBO ,  Hiyoku NAKATA ,  Yasutaka BABA ,  Takashi TAMURA ,  Hidenobu KUNIYOSHI ,  Shinji HAGIWARA ,  Mari YAMAMOTO

IPC分类号： C07D401/12 ,  C07D401/04 ,  C07D213/82 ,  C07D513/04 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/12 ,  C07D401/14 ,  C07D471/04

CPC分类号： C07D401/12 ,  C07D213/82 ,  C07D215/40 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D491/056 ,  C07D491/107 ,  C07D498/04 ,  C07D513/04

摘要： An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

摘要翻译： 本发明的目的是提供具有优异的Syk抑制活性的化合物和药物组合物。 本发明提供下述式（I）表示的烟酰胺衍生物（其中，R1表示卤素原子，R2表示C1-12烷基，C2-12烯基，C2-12炔基，C3-8 环烷基，芳基，芳基-C 1-6烷基或杂环基，各自任选具有至少一个取代基; R 3表示各自任选具有至少一个取代基的芳基或杂环基;以及R 4和R 5各自 独立地表示氢原子; R2和R4可以形成任选具有至少一个取代基的环状氨基以及与它们结合的氮原子）或其盐，以及用于治疗Syk- 其包含烟酰胺衍生物或其盐。

公开(公告)号：US08772320B2

公开(公告)日：2014-07-08

申请号：US13730000

申请日：2012-12-28

申请人： Hideyasu Fujiwara ,  Kimihiko Sato ,  Shinsuke Mizumoto ,  Yuichiro Sato ,  Hideki Kurihara ,  Yohei Kubo ,  Hiyoku Nakata ,  Yasutaka Baba ,  Takashi Tamura ,  Hidenobu Kuniyoshi ,  Shinji Hagiwara ,  Mari Yamamoto

发明人： Hideyasu Fujiwara ,  Kimihiko Sato ,  Shinsuke Mizumoto ,  Yuichiro Sato ,  Hideki Kurihara ,  Yohei Kubo ,  Hiyoku Nakata ,  Yasutaka Baba ,  Takashi Tamura ,  Hidenobu Kuniyoshi ,  Shinji Hagiwara ,  Mari Yamamoto

IPC分类号： C07D213/82

摘要： An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

公开(公告)号：US08809371B2

公开(公告)日：2014-08-19

申请号：US13730000

申请日：2012-12-28

申请人： Hideyasu Fujiwara ,  Kimihiko Sato ,  Shinsuke Mizumoto ,  Yuichiro Sato ,  Hideki Kurihara ,  Yohei Kubo ,  Hiyoku Nakata ,  Yasutaka Baba ,  Takashi Tamura ,  Hidenobu Kuniyoshi ,  Shinji Hagiwara ,  Mari Yamamoto

发明人： Hideyasu Fujiwara ,  Kimihiko Sato ,  Shinsuke Mizumoto ,  Yuichiro Sato ,  Hideki Kurihara ,  Yohei Kubo ,  Hiyoku Nakata ,  Yasutaka Baba ,  Takashi Tamura ,  Hidenobu Kuniyoshi ,  Shinji Hagiwara ,  Mari Yamamoto

IPC分类号： C07D213/82

摘要： An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

公开(公告)号：US08499224B2

公开(公告)日：2013-07-30

申请号：US12730984

申请日：2010-03-24

申请人： Hideyasu Fujiwara

发明人： Hideyasu Fujiwara

IPC分类号： H03M13/00

CPC分类号： H03M13/1515 ,  G06F11/1076 ,  G06F2211/1057 ,  H03M13/158 ,  H03M13/6508

摘要： A redundant code generation method includes: dividing original data into data strings; dividing each data string into a number of bit strings that accords with an extended Galois field operation; storing each of the bit string in a different memory area of a memory; and executing an exclusive OR operation among vectors, which are extracted from the respective bit strings stored in the memory, according to an operational expression to compute bit strings that make up redundant code data strings without carrying out a bit shift operation within the vectors. A predetermined plural number of bits is taken as a data unit and the number of bits as elements constituting each vector is equal to the data unit. The operational expression includes a companion matrix of a primitive polynomial of the Galois field and defined the generation of the redundant code data strings.

摘要翻译： 冗余代码生成方法包括：将原始数据分割成数据串; 将每个数据串划分成符合扩展伽罗瓦域操作的多个位串; 将每个位串存储在存储器的不同存储区域中; 并且根据操作表达式执行从存储在存储器中的各个比特串中提取的向量之中的异或运算，以计算组成冗余码数据串的比特串，而不进行向量内的比特移位操作。 将预定的多个比特作为数据单位，并且作为构成每个向量的元素的比特数等于数据单元。 操作表达式包括伽罗瓦域的原始多项式的伴随矩阵，并且定义了冗余代码数据串的生成。

公开(公告)号：US20100251071A1

公开(公告)日：2010-09-30

申请号：US12730984

申请日：2010-03-24

申请人： HIDEYASU FUJIWARA

发明人： HIDEYASU FUJIWARA

IPC分类号： G06F12/16 ,  H03M13/07 ,  G06F11/10

CPC分类号： H03M13/1515 ,  G06F11/1076 ,  G06F2211/1057 ,  H03M13/158 ,  H03M13/6508

摘要： A redundant code generation method includes: dividing original data into data strings; dividing each data string into a number of bit strings that accords with an extended Galois field operation; storing each of the bit string in a different memory area of a memory; and executing an exclusive OR operation among vectors, which are extracted from the respective bit strings stored in the memory, according to an operational expression to compute bit strings that make up redundant code data strings without carrying out a bit shift operation within the vectors. A predetermined plural number of bits is taken as a data unit and the number of bits as elements constituting each vector is equal to the data unit. The operational expression includes a companion matrix of a primitive polynomial of the Galois field and defined the generation of the redundant code data strings.

摘要翻译： 冗余代码生成方法包括：将原始数据分割成数据串; 将每个数据串划分成符合扩展伽罗瓦域操作的多个位串; 将每个位串存储在存储器的不同存储区域中; 并且根据操作表达式执行从存储在存储器中的各个位串中提取的向量之中的异或运算，以计算构成冗余代码数据串的位串，而不进行向量内的位移操作。 将预定的多个比特作为数据单位，并且作为构成每个向量的元素的比特数等于数据单元。 操作表达式包括伽罗瓦域的原始多项式的伴随矩阵，并且定义了冗余代码数据串的生成。